The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis

Platinum-based chemotherapeutic drugs are widely used as components of combination chemotherapy in the treatment of cancer. One such drug, oxaliplatin, exerts a synergistic effect against advanced colorectal cancer in combination with 5-fluorouracil (5-FU) and leucovorin. In the p53-proficient colorectal cancer cell line HCT116, oxaliplatin represses the expression of deoxyuridine triphosphatase (dUTPase), a ubiquitous pyrophosphatase that catalyzes the hydrolysis of dUTP to dUMP and inhibits dUTP-mediated cytotoxicity. However, the underlying mechanism of this activity has not been completely elucidated, and it remains unclear whether factors other than downregulation of dUTPase contribute to the synergistic effect of 5-FU and oxaliplatin. In this study, we found that oxaliplatin and dachplatin, platinum-based drugs containing the 1,2-diaminocyclohexane (DACH) carrier ligand, repressed the expression of nuclear isoform of dUTPase (DUT-N), whereas cisplatin and carboplatin did not. Oxaliplatin induced early p53 accumulation, upregulation of primary miR-34a transcript expression, and subsequent downregulation of E2F3 and E2F1. Nutlin-3a, which activates p53 nongenotoxically, had similar effects. Introduction of miR-34a mimic also repressed E2F1 and DUT-N expression, indicating that this miRNA plays a causative role. In addition to DUT-N, oxaliplatin repressed, in a p53-dependent manner, the expression of genes encoding enzymes involved in thymidylate biosynthesis. Consequently, oxaliplatin significantly decreased the level of dTTP in the dNTP pool in a p53-dependent manner. These data indicate that the DACH carrier ligand in oxaliplatin triggers signaling via the p53–miR-34a–E2F axis, leading to transcriptional regulation that ultimately results in accumulation of dUTP and reduced dTTP biosynthesis, potentially enhancing 5-FU cytotoxicity. Mol Cancer Ther; 14(10); 2332–42. ©2015 AACR.

[1]  E. Tokunaga,et al.  Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks , 2015, Molecular Cancer Therapeutics.

[2]  P. Johnston,et al.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy , 2014, Nature Reviews Clinical Oncology.

[3]  Y. Fujimura,et al.  Metabolomics reveals that carnitine palmitoyltransferase‐1 is a novel target for oxidative inactivation in human cells , 2013, Genes to cells : devoted to molecular & cellular mechanisms.

[4]  T. Hasunuma,et al.  Widely targeted metabolic profiling analysis of yeast central metabolites. , 2012, Journal of bioscience and bioengineering.

[5]  H. Lenz,et al.  Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase–Targeted Therapies in Non–Small Cell Lung Cancer , 2011, Molecular Cancer Therapeutics.

[6]  N. Petrelli,et al.  Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Parle‐McDermott,et al.  The former annotated human pseudogene dihydrofolate reductase-like 1 (DHFRL1) is expressed and functional , 2011, Proceedings of the National Academy of Sciences.

[8]  A. Khokhar,et al.  The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog. , 2011, Gynecologic oncology.

[9]  H. Krokan,et al.  UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation , 2011, Nucleic acids research.

[10]  P. Wilson,et al.  A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates , 2011, Nucleic acids research.

[11]  M. Sana,et al.  miR-34a Induces the Downregulation of Both E2F1 and B-Myb Oncogenes in Leukemic Cells , 2011, Clinical Cancer Research.

[12]  Jui‐I Chao,et al.  Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells. , 2010, Chemico-biological interactions.

[13]  Joon-Oh Park,et al.  Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy , 2010, Cancer Chemotherapy and Pharmacology.

[14]  B Munch-Petersen,et al.  Enzymatic Regulation of Cytosolic Thymidine Kinase 1 and Mitochondrial Thymidine Kinase 2: A Mini Review , 2010, Nucleosides, nucleotides & nucleic acids.

[15]  P. Validire,et al.  Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  I. B. Borel Rinkes,et al.  Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa , 2010, British Journal of Cancer.

[17]  M. Honda,et al.  dUTP pyrophosphatase expression correlates with a poor prognosis in hepatocellular carcinoma , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[18]  H. Hermeking.  The miR-34 family in cancer and apoptosis , 2010, Cell Death and Differentiation.

[19]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Vértessy,et al.  Keeping uracil out of DNA: physiological role, structure and catalytic mechanism of dUTPases. , 2009, Accounts of chemical research.

[21]  H. Lenz,et al.  Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage , 2008, Nucleic acids research.

[22]  N. Neamati,et al.  Novel opportunities for thymidylate metabolism as a therapeutic target , 2008, Molecular Cancer Therapeutics.

[23]  J. Espinosa,et al.  Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation , 2008, Cell cycle.

[24]  K. Cimprich,et al.  ATR: an essential regulator of genome integrity , 2008, Nature Reviews Molecular Cell Biology.

[25]  Shaomeng Wang,et al.  Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer , 2008, Molecular Cancer Therapeutics.

[26]  H. Hermeking.  p53 enters the microRNA world. , 2007, Cancer cell.

[27]  Naoto Tsuchiya,et al.  Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells , 2007, Proceedings of the National Academy of Sciences.

[28]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[29]  Stephen J Lippard,et al.  Direct cellular responses to platinum-induced DNA damage. , 2007, Chemical reviews.

[30]  S. Galiègue,et al.  Repression of cell cycle–related proteins by oxaliplatin but not cisplatin in human colon cancer cells , 2006, Molecular Cancer Therapeutics.

[31]  N. Bastien,et al.  SW480, a p53 double-mutant cell line retains proficiency for some p53 functions. , 2005, Journal of molecular biology.

[32]  R. Ladner,et al.  Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition. , 2004, Molecular pharmacology.

[33]  K. Yeh,et al.  Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells , 2004, Anti-cancer drugs.

[34]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[35]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[36]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[37]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Groshen,et al.  dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. , 2000, Cancer research.

[39]  L. Johnson,et al.  Transcriptional control elements and complex initiation pattern of the TATA‐less bidirectional human thymidylate synthase promoter , 2000, Journal of cellular biochemistry.

[40]  S. Jackson,et al.  Regulation of p53 in response to DNA damage , 1999, Oncogene.

[41]  G. Pfeifer,et al.  Constitutive Protection of E2F Recognition Sequences in the Human Thymidine Kinase Promoter during Cell Cycle Progression* , 1997, The Journal of Biological Chemistry.

[42]  Shiaw-Yih Lin,et al.  Cell cycle-regulated association of E2F1 and Sp1 is related to their functional interaction , 1996, Molecular and cellular biology.

[43]  J. Nevins,et al.  Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. , 1994, Genes & development.

[44]  Liquid Biopsies.  Non-small-cell lung cancer , 2015, Nature Reviews Disease Primers.

[45]  T. Alcindor,et al.  Drug Development in Contemporary Oncology Methods of Study Selection , 2022 .

[46]  R. Ogawa.  [Down regulation]. , 1998, Masui. The Japanese journal of anesthesiology.